ASPIRA PATHLAB & DIAGNOSTICS | N.G.IND.LTD. | ASPIRA PATHLAB & DIAGNOSTICS / N.G.IND.LTD. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.6 | 13.2 | - | View Chart |
P/BV | x | 2.6 | 2.0 | 130.3% | View Chart |
Dividend Yield | % | 0.0 | 2.1 | - |
ASPIRA PATHLAB & DIAGNOSTICS N.G.IND.LTD. |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
N.G.IND.LTD. Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / N.G.IND.LTD. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 99 | 75.8% | |
Low | Rs | 26 | 60 | 42.5% | |
Sales per share (Unadj.) | Rs | 14.0 | 55.8 | 25.2% | |
Earnings per share (Unadj.) | Rs | -0.1 | 24.8 | -0.3% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 26.4 | 5.5% | |
Dividends per share (Unadj.) | Rs | 0 | 3.50 | 0.0% | |
Avg Dividend yield | % | 0 | 4.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 12.4 | 84.2 | 14.7% | |
Shares outstanding (eoy) | m | 10.29 | 3.35 | 307.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 1.4 | 251.1% | |
Avg P/E ratio | x | -583.7 | 3.2 | -18,187.6% | |
P/CF ratio (eoy) | x | 34.6 | 3.0 | 1,146.3% | |
Price / Book Value ratio | x | 4.1 | 0.9 | 429.3% | |
Dividend payout | % | 0 | 14.1 | -0.0% | |
Avg Mkt Cap | Rs m | 518 | 267 | 194.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 21 | 264.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 187 | 77.3% | |
Other income | Rs m | 3 | 84 | 3.8% | |
Total revenues | Rs m | 148 | 271 | 54.6% | |
Gross profit | Rs m | 16 | 19 | 84.5% | |
Depreciation | Rs m | 16 | 5 | 302.1% | |
Interest | Rs m | 4 | 1 | 484.9% | |
Profit before tax | Rs m | -1 | 96 | -0.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 13 | 0.0% | |
Profit after tax | Rs m | -1 | 83 | -1.1% | |
Gross profit margin | % | 11.0 | 10.1 | 109.3% | |
Effective tax rate | % | 0 | 13.8 | -0.0% | |
Net profit margin | % | -0.6 | 44.5 | -1.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 30 | 195.8% | |
Current liabilities | Rs m | 16 | 19 | 84.7% | |
Net working cap to sales | % | 29.5 | 6.0 | 493.2% | |
Current ratio | x | 3.7 | 1.6 | 231.1% | |
Inventory Days | Days | 88 | 440 | 20.0% | |
Debtors Days | Days | 590 | 1,373 | 43.0% | |
Net fixed assets | Rs m | 115 | 277 | 41.4% | |
Share capital | Rs m | 103 | 34 | 307.2% | |
"Free" reserves | Rs m | 25 | 249 | 9.9% | |
Net worth | Rs m | 128 | 282 | 45.2% | |
Long term debt | Rs m | 10 | 0 | - | |
Total assets | Rs m | 173 | 307 | 56.5% | |
Interest coverage | x | 0.8 | 113.2 | 0.7% | |
Debt to equity ratio | x | 0.1 | 0 | - | |
Sales to assets ratio | x | 0.8 | 0.6 | 136.9% | |
Return on assets | % | 1.9 | 27.4 | 6.9% | |
Return on equity | % | -0.7 | 29.5 | -2.4% | |
Return on capital | % | 2.4 | 34.5 | 6.9% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 32 | -0.4% | |
From Investments | Rs m | 2 | -17 | -9.3% | |
From Financial Activity | Rs m | -9 | -11 | 84.2% | |
Net Cashflow | Rs m | -8 | 3 | -237.3% |
Indian Promoters | % | 18.7 | 74.5 | 25.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 25.5 | 318.9% | |
Shareholders | 1,512 | 2,088 | 72.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS NARAYANA HRUDAYALAYA METROPOLIS HEALTHCARE KIMS
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | N.G.IND.LTD. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.27% | 0.69% | 0.20% |
1-Month | -2.29% | -0.51% | 0.11% |
1-Year | -3.03% | 116.69% | 54.09% |
3-Year CAGR | 2.29% | 54.60% | 14.99% |
5-Year CAGR | -1.66% | 22.33% | 19.84% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the N.G.IND.LTD. share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of N.G.IND.LTD. the stake stands at 74.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of N.G.IND.LTD..
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
N.G.IND.LTD. paid Rs 3.5, and its dividend payout ratio stood at 14.1%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of N.G.IND.LTD..
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.